Alpha-9 Oncology Secures $175M Series C to Drive Radiopharmaceutical Innovation in Cancer Treatment

Boston, MA and Vancouver, Canada, October 23, 2024 (PRNewswire) -- Alpha-9 Oncology has raised $175 million in Series C funding to advance its radiopharmaceutical pipeline for cancer treatment. The investment will support clinical studies, discovery efforts, and manufacturing expansion. The financing round was led by top investors, further solidifying Alpha-9's leadership in radiopharmaceuticals.

Read full article here.